Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2025-12-24 @ 2:08 PM
NCT ID:
NCT07091695
Eligibility Criteria:
Inclusion Criteria:
* Participants at least 18 years old at diagnosis of clinically palpable stage III resectable melanoma
* Participants treated with nivolumab+relatimab (nivo+rela) or nivolumab+ipilimumab (nivo+ipi) in the neoadjuvant setting
* Participants with at least 6 months of follow-up from initiation of neoadjuvant therapy, unless deceased prior to 6 months of follow-up
Exclusion Criteria:
* Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial
* Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years.
* Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi
* Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela
* Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07091695
Study Brief:
Protocol Section:
NCT07091695